Haematopoiesis

Haematopoiesis describes the biological process through which all blood cells are generated and maintained, originating primarily in bone marrow from haematopoietic stem cells that differentiate into erythrocytes, leukocytes, and platelets. This tightly regulated system balances continuous blood cell production with physiological demands, responding dynamically to infection, inflammation, bleeding, or chemotherapy-induced suppression.

The biopharmaceutical industry focuses extensively on haematopoiesis due to its central role in oncology supportive care, transplantation, and immune system recovery. Many anticancer therapies suppress bone marrow function, creating clinical needs for agents that stimulate haematopoiesis and reduce complications like neutropenia or anaemia. Therapeutics including colony-stimulating factors and erythropoiesis-stimulating agents support blood cell recovery. Drug development evaluates haematopoietic toxicity as a major safety endpoint. As cell therapies advance and gene editing targets haematopoietic stem cells for inherited disorders, understanding haematopoiesis remains essential for designing effective treatments and ensuring long-term patient outcomes.